RESEARCH ARTICLE

Potential use of supervised injection services among people who inject drugs in a remote and mid-size Canadian setting

Sanjana Mitra¹,², Beth Rachlis³,⁴, Bonnie Krysowaty⁵, Zack Marshall⁶, Cynthia Olsen⁷, Sean Rourke⁸,⁹ and Thomas Kerr¹,¹⁰*

Abstract

Background: While supervised injection services (SIS) feasibility research has been conducted in large urban centres across North America, it is unknown whether these services are acceptable among people who inject drugs (PWID) in remote, mid-size cities. We assessed willingness to use SIS and expected frequency of SIS use among PWID in Thunder Bay, a community in Northwestern, Ontario, Canada, serving people from suburban, rural and remote areas of the region.

Methods: Between June and October 2016, peer research associates administered surveys to PWID. Sociodemographic characteristics, drug use and behavioural patterns associated with willingness to use SIS and expected frequency of SIS use were estimated using bivariable and multivariable logistic regression models. Design preferences and amenities identified as important to provide alongside SIS were assessed descriptively.

Results: Among 200 PWID (median age, IQR: 35, 28–43; 43% female), 137 (69%) reported willingness to use SIS. In multivariable analyses, public injecting was positively associated with willingness to use (Adjusted Odds Ratio (AOR): 4.15; 95% confidence interval (CI): 2.08–8.29). Among those willing to use SIS, 87 (64%) said they would always/usually use SIS, while 48 (36%) said they would sometime/occasionally use SIS. In multivariable analyses, being female (AOR: 2.44; 95% CI: 1.06–5.65) and reporting injecting alone was positively associated with higher expected frequency of use (AOR: 2.59; 95% CI: 1.02–6.58).

Conclusions: Our findings suggest that SIS could play a role in addressing the harms of injection drug use in remote and mid-sized settings particularly for those who inject in public, as well as women and those who inject alone, who report higher expected frequency of SIS use. Design preferences of local PWID, in addition to differences according to gender should be taken into consideration to maximize the uptake of SIS, alongside existing health and social service provisions available to PWID.

Keywords: Supervised injection services, Supervised consumption facilities, Feasibility research, People who inject drugs, Mid-sized cities, Remote communities

* Correspondence: bccsu-tk@bccsu.ubc.ca
¹British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada
¹⁰Department of Medicine, University of British Columbia, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Cities across North America are contending with epidemics of opioid use and fatal drug poisoning linked to injection drug use, as well as other associated harms such as soft tissue infections, endocarditis and blood-borne infections [1–4]. Beyond the individual-level health-related harms experienced by people who inject drugs (PWID), injection drug use in public spaces is perceived as a major community concern, contributing to the improper disposal of syringes and other injection-related materials [5]. Further, costs associated with hospital utilization and emergency room visits related to injection drug use increase the financial burden on health care systems [6, 7].

To address the individual and structural risks associated with injection drug use, supervised injection services (SIS) offer safe and hygienic conditions where people can inject previously obtained illicit substances under medical supervision [8, 9]. The services can also provide clients access to sterile injecting equipment and connections to basic medical care as well as referrals to other health and social services [9]. SIS have been implemented in many settings, including Western Europe and Australia [10]. In Canada, two long-standing SIS have been operating in Vancouver for over a decade [11, 12], with new sites opening in urban centres across British Columbia, Ontario, Alberta and Quebec in the past year [13, 14].

Rigorous evaluations of SIS in Vancouver, Canada and Sydney, Australia have established that SIS have beneficial effects on the communities in which they are situated, improving health and social outcomes associated with injection drug use [5, 15–20]. The services have been attributed to reducing the risk of transmission of blood-borne infections [16, 18] and fatal overdose [17], while increasing the uptake of medical care and addiction treatment [19, 20]. SIS have also been shown to reduce public injecting and improperly disposed syringes and injection-related litter [5, 21], in addition to decreasing the number of overdose-related ambulance attendances in the immediate vicinity of the service [15].

Feasibility research has been used previously to inform the implementation of SIS and establish the acceptability and willingness to use the service among PWID [22–26]. Research also suggests that intention to use SIS has been shown to predict actual use of SIS once such services are established [27]. Despite the need for widespread evidence-based harm reduction services in remote settings where drug use is a major concern [28, 29], a majority of research remains focused on PWID in urban settings. To-date, SIS feasibility research has been conducted in mid- to large-size North American urban centres [22–26], and as such, little is known about the acceptability and design preferences of SIS among PWID in remote settings.

Thunder Bay is a mid-sized city situated in the outlying and expansive region of Northwestern Ontario, Canada with a metropolitan population of 121,600 [30–32]. Located on the northern shore of Lake Superior, it is the most populous municipality in all of Northwestern Ontario (see Fig. 1 for map of Thunder Bay’s location). Since Thunder Bay is remotely situated from other neighbouring towns and cities, the city acts as a regional hub for surrounding rural and remote communities [30]. The Thunder Bay District Health Unit (TBDHU) which includes the City of Thunder Bay, oversees a geographic area of approximately 230,000 km² and 146,000 residents [33]. Within the City of Thunder Bay, health and social service coverage spans large geographic areas and is intended to be reached by residents living in suburban, rural, and remote communities.

Illustrated by the present opioid and overdose crises spanning North America, many mid-size and remote cities are contending with issues related to overdose and injection drug use similar to that of larger urban centres [34]. Nonetheless, some evidence indicates that smaller and mid-size cities may experience different barriers to SIS implementation compared to larger urban centres. Common barriers experienced by PWID living in smaller and more remote communities include restricted access to a coordinated system of harm reduction services and addiction treatment, and concerns related to a lack of confidentiality and privacy when accessing substance use related care [29, 35]. Dispersed population density spanning large geographic areas in remote settings may further contribute to difficulty accessing services as a result of long distances to travel and inconsistent access to transportation [29]. Furthermore, some social norms characteristic of smaller and remote communities may introduce barriers related to access and implementation of harm reduction services. Compared to larger urban centres, smaller and more remote communities may sometimes face stringent views of individualism, self-sufficiency and conservatism toward substance use [29, 36]. Resulting stigma and discrimination may lead to social isolation or individuals choosing not to disclose their drug use, therefore making it challenging for some PWID to seek care [36]. Despite feasibility study results from another mid-size Canadian setting that found contrasting evidence to past research that suggests smaller cities lack liberal perspectives toward harm reduction and injection drug use [24], it remains unclear how these concerns may relate to the implementation of SIS in a geographically outlying mid-size city servicing suburban, rural and remote communities.

While there is limited information available on injection drug use in Thunder Bay, existing data suggests that the municipality has a disproportionately large
population of PWID that is contending with a range of drug-related harms [37]. A 2013 community needs assessment revealed that the rate of non-prescription opioid use in Thunder Bay was higher than the provincial average (3.0% versus 1.7%) [38]. A 2018 surveillance report illustrated that between 2012 and 2016, the rate of emergency department visits for opioid overdose in the Thunder Bay region remained almost double that of the province of Ontario (ranging from 54.6–53.1 per 100,000 versus 23.5–31.7 per 100,000) [39]. With regards to injection drug use, a 2014 survey of PWID in Thunder Bay indicated high rates of needle and syringe borrowing and lending in the previous 6 months, at 19 and 21% respectively [40]. An enhanced surveillance reporting system among PWID across Canada revealed that between 2006-2007 and 2010–2012, the proportion of participants who injected opioids in the past 6 months in Thunder Bay substantially increased for almost all opioids, including morphine, oxycodone and fentanyl (an increase of 12.3, 35.4, and 7.1% respectively) [41]. Further, HCV rates in Thunder Bay are the second highest in the province of Ontario, and among those who reported injection drug use, 51% had lifetime exposure to HCV [40].

Thunder Bay supports one of the busiest needle syringe programs in the province [42], where clients can access sterile injection equipment such as needles, syringes, filters and cookers, are encouraged to return or properly dispose of needles or syringes after use, and are educated about the risks of using non-sterile equipment [43]. Nonetheless, concerns related to injection drug use in Thunder Bay persist [44]. While community services are in place in relation to housing programs and addiction treatment, they are not always accessible due to long wait times. Although Thunder Bay’s local drug strategy is calling for the further development of harm reduction approaches [45], there remains a lack of SIS feasibility research conducted in remote settings, and the potential role and acceptability of these services in Thunder Bay remains unknown. Therefore, we sought to characterize willingness to use SIS and expected frequency of SIS use among PWID in Thunder Bay,
Canada and explored design and operational preferences among PWID.

Methods
Data were derived from the Ontario Integrated Supervised Injection Services (OISIS) Feasibility Study, a cross-sectional study of PWID Thunder Bay, Ontario, Canada [46, 47]. The study was supported by the Ontario HIV Treatment Network in partnership with the Canadian Institutes of Health Research Centre for REACH in HIV/AIDS and the Thunder Bay Drug Strategy, a local coalition of more than 30 partner agencies and people with lived experience. It was also overseen by an Advisory Committee comprised of local healthcare and social service providers, and other key stakeholders.

Between June and October 2016, the research team worked with two trained peer research associates (PRAs) to recruit participants through city-wide peer outreach efforts, word of mouth, and recruitment flyers posted at local health and social service agencies. Eligibility criteria included being 18 or older and having injected drugs in the last 6 months. Potential participants were invited for an appointment or drop-in interview at one of three community sites. PRAs administered a quantitative survey programmed on electronic tablets to study participants. The survey took approximately 45 min to complete and was adapted from previous SIS feasibility studies [26]. Information elicited from the questionnaire included socio-demographics, social-structural exposures, drug-using behaviours and patterns, access to health services, willingness to use and operational preferences for SIS. All participants received a $25 honorarium and provided written informed consent. This study was approved by the University of Toronto and the University of British Columbia’s research ethics boards.

Measures and outcomes
Our primary outcomes of interest were willingness to use SIS and expected frequency of SIS use. Study participants were first asked “Have you heard of supervised injection services (SISs)?” with response options that included yes and no. If participants responded no, they were asked the following script and description of SIS: “For this interview, we want to use the same definition of SISs, to make sure that we’re talking about the same type of place. A supervised injecting service is a legally operated indoor facility where people come to inject their own drugs under the supervision of medically trained workers. People can inject there under safe and sterile conditions and have access to all sterile injecting equipment (cotton, cooker, water, etc.) and receive basic medical care and/or be referred to appropriate health or social services.” For willingness to use, response options were dichotomized into yes (i.e. those willing to use SIS) and maybe/no (i.e. those who may be willing or not willing to use SIS). For expected frequency of SIS use, study participants were asked “If a SIS was established in a location convenient to you, how often would you use it?”. Response options included: always (100% of injections), usually (over 75% of injections), sometimes (between 25 and 75% of injections), occasionally (less than 25% of injections), and never and were subsequently dichotomized into always/usually and sometime/occasionally (i.e. “high” and “low” expected frequency of SIS use, respectively).

A range of socio-demographic variables were considered for this analysis, including gender (female versus male), age (in years), ethnicity (white versus other, defined as Black, First Nations, Metis, Inuit, Francophone, South Asian, East Asian, Arab/West Asian, Latin American/Central American/South American) and engagement in sex work in the past 6 months (yes versus no). Housing status was also considered. Given the number of housing response options available, to increase interpretability, a binary variable was created (homeless or unstably housed [including living in a place where people gather to use drugs, hospital, rented hotel/motel room, no fixed address, on the street, prison/jail/detention centre, rehab, rooming or boarding house, shelter or welfare residence, medical hostel, or transitional housing] versus living alone, with a partner, or with family/friends in a house or apartment). Drug use behaviours and patterns in past 6 months were considered and included: any public injecting (yes versus no), any injecting alone (yes versus no), any help needed during injecting (yes versus no), any syringe sharing (categorized as borrowing or loaning; yes versus no), daily opioid injecting, daily cocaine injecting, daily rock cocaine injecting (all defined as daily versus less than daily or never) and any Wellbutrin, Ritalin or Biphentin injecting (yes versus no). Given polysubstance use is common among PWID [48], frequency of use for most drugs were defined as daily versus less than daily or never to get a better sense of the primary substance used by an individual, and to distinguish between drug use intensities, both of which are important considerations in relation to willingness to use SIS. We also assessed lifetime history of drug overdose (yes versus no) and lifetime history of drug treatment (including past use of one or a combination of detox programs, opioid substitution therapy, addiction case management, drug court, residential drug treatment, and outpatient counselling; yes versus no).

Finally, data were obtained on design and operational preferences and included preferred set-up for injecting space, willingness to use an integrated service (i.e. providing SIS alongside other health services, including but
not limited to basic medical care, access to sterile needles and injecting equipment, harm reduction education, and HIV/HCV testing), willingness to walk or bus, desired hours of operation, involvement of PWID in service delivery, and important amenities to provide alongside SIS (See Table 3 for a range of questions asked).

**Data analysis**

Using descriptive statistics stratified by our primary outcomes of interest, we reported proportions for categorical variables and the median (and interquartile range) for age as a continuous variable. To model socio-demographic and drug using behaviours associated with the outcomes of interest, willingness to use SIS and expected frequency of SIS use, we used logistic regression. All variables were entered into a full multivariable logistic model to adjust for suspected and potential confounders. In a backwards, step-wise manner, we dropped the least significant variable from the full model unless dropping the variable changed the statistical significance of other variables or resulted in potential changes in the point estimate. In an iterative process, reduced models were refit until all retained variables were either significant ($p < 0.05$) or identified as potential confounders. We also reported design and operational preferences and important amenities for using SIS stratified by gender. All analyses were conducted in SAS 9.4 [49].

**Results**

Of 200 participants who provided complete data on willingness to use SIS (Table 1), the median age was 35 years (IQR: 28–43), 43% were female and 63% had previously heard of SIS. Sixty-nine percent ($n = 137$) reported willingness to use SIS. In bivariable analyses, those who expressed willingness to use were more likely to be unstably housed (Odds Ratio (OR): 2.10; 95% confidence interval (CI): 1.08–3.74) and more likely to report public injecting (OR: 4.61; 95% CI: 2.44–8.70), daily cocaine injecting (OR: 2.78; 95% CI: 1.09–7.05) and involvement in sex work (OR: 5.61; 95% CI: 1.64–19.15). Wide CIs for the estimate of sex work may be explained by low cell counts, particularly among those not willing or maybe willing to use SIS and engaging in sex work. In multivariable analyses, any public injecting in the last 6 months (Adjusted Odds Ratio (AOR): 4.15; 95% CI: 2.08–8.29) remained positively associated with willingness to use SIS.

Of the 137 who reported willingness to use SIS, 135 (99%) provided complete data on expected frequency of SIS use (Table 2). Among those willing to use, 87 (64%) said they would always/usually use SIS, whereas 48 (36%) said they would use it sometimes/occasionally. In bivariable analyses, higher expected frequency of use was positively associated with being female (OR: 2.37; 95% CI: 1.12–5.03) and reporting any injecting alone (OR: 2.63; 95% CI: 1.09–6.34) and daily opioid injecting (OR: 3.15; 95% CI: 1.20–8.30). In multivariable analyses, being female (AOR: 2.44; 95% CI: 1.06–5.65) and any injecting alone (AOR: 2.59; 95% CI: 1.02–6.58) remained positively associated with higher expected frequency of use.

Table 3 presents design and operational preferences among those willing to use SIS, stratified by gender. Of those willing to use SIS, 76% preferred private cubicle set-up for an injecting space, 63% preferred daytime operating hours, and 52% believed PWID should be involved in daily SIS operations. No differences were reported by gender. Eighty-eight percent were willing to walk to access SIS, while 78% were willing to take a bus. Women were less likely to report willingness to walk or bus 20 min or more to access SIS compared to men. Top services considered to be important to provide alongside SIS included distribution of needle and sterile injecting equipment, preventing and responding to overdose, HIV/HCV testing, and access to other health services. No differences were reported by gender.

**Discussion**

We found moderately high levels of willingness to use SIS among PWID in the remote and mid-sized city of Thunder Bay, Canada. Willingness to use SIS was positively associated with public injecting in the last 6 months. Among those who expressed willingness to use SIS, higher expected frequency of SIS use was associated with being female and reporting any injecting alone in the past 6 months. PWID also expressed design and operational preferences, in addition to identifying other health and harm reduction services to provide alongside SIS.

Several North American urban centres have undertaken SIS feasibility research to determine the acceptability and role of SIS within communities [22–26]. Overall, levels of willingness to use SIS among large North American cities have been found to be high, ranging from 75 to 92% [22, 23, 26]. As a part of the Ontario Integrated Supervised Injection Services (OiSIS) [46, 47] Feasibility Study, recently published findings from a mid-sized urban centre found high levels of willingness to use SIS among PWID at 86% [24]. At 69%, we found a somewhat lower level of willingness to use SIS among PWID in this setting.

One possible explanation for the lower rate of willingness to use SIS in this context is related to stigma associated with injection drug use [29]. Rural and remote communities often contend with less liberal attitudes towards certain behaviours, including injection drug use [29, 36]. PWID from these communities may also lack anonymity [36] when accessing services and may
Table 1 Socio-demographic, drug use characteristics and treatment history characteristics associated with willingness to use SIS (n = 200)

| Characteristic                      | Total sample (n = 200) | Willingness to use SIS | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|-------------------------------------|------------------------|------------------------|------------------------|----------------------|
|                                     |                        | Yes (n = 137)          | No or Maybe (n = 63)   |                      |
|                                     |                        | n (%)                  | n (%)                  |                      |
| Age, yr                             |                        |                        |                        |                      |
| Median (IQR)                        | 35 (28–43)             | 34 (27–43)             | 37 (28–46)             | 0.99 (0.96–1.02)     | 1.02 (0.98–1.05)     |
| Gender                              |                        |                        |                        |                      |
| Male                                | 114 (57.0)             | 78 (68.4)              | 36 (31.5)              | 0.99 (0.54–1.81)     | 0.94 (0.47–1.85)     |
| Female                              | 86 (43.0)              | 59 (68.6)              | 27 (31.4)              | 1.02 (0.98–1.05)     |                      |
| Ethnicity                           |                        |                        |                        |                      |
| White                               | 53 (26.5)              | 31 (58.5)              | 22 (41.5)              | 1.84 (0.95–3.53)     | 1.77 (0.81–3.87)     |
| Other                               | 147 (73.5%)            | 106 (72.1)             | 41 (27.9)              |                       |                      |
| Housing                             |                        |                        |                        |                      |
| Unstable/Homeless                   | 133 (66.5)             | 98 (73.7)              | 35 (26.3)              | 2.10* (1.08–3.74)    | 1.54 (0.75–3.16)     |
| Stable                              | 67 (33.5)              | 39 (58.2)              | 28 (41.8)              |                       |                      |
| Sex work                            |                        |                        |                        |                      |
| Yes                                 | 33 (16.5)              | 30 (90.9)              | 3 (9.1)                | 5.61* (1.64–19.15)   | -                    |
| No                                  | 167 (83.5)             | 107 (64.1)             | 60 (35.9)              |                       |                      |
| Any public injecting*               |                        |                        |                        |                      |
| Yes                                 | 128 (64.0)             | 103 (80.5)             | 25 (19.5)              | 4.61* (2.44–8.70)    | 4.15* (2.08–8.29)    |
| No                                  | 72 (36.0)              | 34 (47.2)              | 38 (52.8)              |                       |                      |
| Any injecting alone*                |                        |                        |                        |                      |
| Yes                                 | 155 (78.0)             | 111 (71.6)             | 44 (28.4)              | 1.75 (0.87–3.50)     | -                    |
| No                                  | 44 (22.0)              | 26 (59.1)              | 18 (40.9)              |                       |                      |
| Any help injecting*                 |                        |                        |                        |                      |
| Yes                                 | 76 (38.0)              | 54 (71.1)              | 22 (28.9)              | 1.21 (0.65–2.25)     | -                    |
| No                                  | 124 (62.0)             | 83 (66.9)              | 41 (33.1)              |                       |                      |
| Syringe sharing*                    |                        |                        |                        |                      |
| Yes                                 | 23 (11.8)              | 14 (60.9)              | 9 (39.1)               | 0.71 (0.29–1.75)     | -                    |
| No                                  | 172 (88.2)             | 118 (68.6)             | 54 (31.4)              |                       |                      |
| Daily opioid*injecting*             |                        |                        |                        |                      |
| Yes                                 | 45 (22.5)              | 33 (73.3)              | 12 (26.7)              | 1.35 (0.64–2.83)     | -                    |
| No                                  | 155 (77.5)             | 104 (67.1)             | 51 (32.7)              |                       |                      |
| Daily cocaine injecting*             |                        |                        |                        |                      |
| Yes                                 | 37 (18.5)              | 31 (83.8)              | 6 (16.2)               | 2.78* (1.09–7.05)    | 1.97 (0.73–5.31)     |
| No                                  | 163 (81.5)             | 106 (65.0)             | 57 (35.0)              |                       |                      |
| Daily crack/rock cocaine injecting*  |                        |                        |                        |                      |
| Yes                                 | 21 (10.5)              | 17 (80.9)              | 4 (19.0)               | 2.09 (0.67–6.49)     | -                    |
| No                                  | 179 (89.5)             | 120 (67.0)             | 59 (32.9)              |                       |                      |
| Any Wellbutrin injecting*           |                        |                        |                        |                      |
| Yes                                 | 67 (33.5)              | 51 (76.1)              | 16 (23.9)              | 1.74 (0.90–3.39)     | -                    |
| No                                  | 133 (66.5)             | 86 (64.7)              | 47 (35.3)              |                       |                      |
| Any Ritalin or Biphentin injecting*  |                        |                        |                        |                      |
| Yes                                 | 75 (37.5)              | 56 (74.7)              | 19 (25.3)              | 1.60 (0.85–3.02)     | -                    |
| No                                  | 125 (62.5)             | 81 (64.8)              | 44 (35.2)              |                       |                      |
experience fear surrounding breaches in confidentiality by healthcare providers [29]. Indeed, previous research has indicated that stigma related to injection drug use, and the consequent fear of disclosing one’s drug using behaviour through accessing services may prevent PWID from seeking appropriate treatment and care, and lead to reluctance to use such services [29]. This may be further complicated by socio-economic risk factors, including homelessness, food insecurity and poverty [29, 50]. Past successful strategies to address stigma associated with injection drug use and accessing harm reduction services in settings like Thunder Bay, which may also be considered when implementing SIS, include public media and education campaigns on the local realities of drug use [51], in addition to involvement of all affected communities in the planning and implementation of SIS to ensure respect and cultural safety.

While SIS appears acceptable among most PWID surveyed in Thunder Bay, it is important to consider the unique challenges that face health and social service practitioners providing care to suburban, rural, and remote populations accessing care in Thunder Bay. A majority of services, including harm reduction and addiction treatment in remote communities often remain underfunded and underserviced, with geographically extensive catchment areas, resulting in inadequate coverage and networks of care [28, 29]. Gaps in care are further complicated by long distances to services, and inconsistent public transportation [29]. Such limitations should be considered in the implementation of SIS.

Similar to previous SIS feasibility research, we found that willingness to use SIS was associated with injecting in public and semi-public spaces [22–24]. Public injection is viewed as a public nuisance within communities as a result of improperly discarded injection-related litter [5]. The act also poses risk to individual health through rushed injection practices and inability to ensure safety, privacy, and hygiene, resulting in an increased risk of syringe sharing, transmission of blood-borne infections and overdose [52–55]. Past evaluations have found that SIS can reduce risk of HIV transmission, syringe sharing, and fatal overdose among PWID, while also improving public order by reducing discarded syringes and injection related litter [5]. In this way, SIS may be an effective approach to reducing both the health and social harms associated with public injecting.

Among those who are willing to use SIS, we found that those who injected alone, and women reported higher expected frequency of SIS use. The harms associated with injecting alone have been well established in previous work. Individuals who inject alone are at elevated risk for fatal overdose [56–58] and have also been shown to be less knowledgeable about blood-borne infections, and less likely to attend harm reduction programs and addiction treatment [58]. The high expected frequency of SIS use among those who inject alone presents a crucial opportunity to prevent fatal overdose, and provide education on harm reduction and safe injection practices to this particularly vulnerable group. This finding is timely, and of significant importance given the present opioid and overdose epidemics affecting communities across North America [34].

Gender differences between men and women with respect to substance use, risk dynamics, and barriers to accessing addiction treatment have been well established [59, 60]. Compared to men who use drugs, women who use drugs experience increased threats of violence and greater stigma related to drug use, resulting in fear and shame and reluctance to seek appropriate care [61–63]. However, past research indicates that SIS can create a safe space for women who use drugs from the threats of violence in local drug scenes [64]. The role of harm reduction services, including SIS may be particularly important for women in Thunder Bay, given income security, limited access to childcare, and safe and affordable housing have been identified as major concerns for

### Table 1 Socio-demographic, drug use characteristics and treatment history characteristics associated with willingness to use SIS (n = 200) (Continued)

| Characteristic          | Total sample (n = 200) | Willingness to use SIS | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|-------------------------|------------------------|------------------------|------------------------|----------------------|
|                         | Yes (n = 137)          | No or Maybe (n = 63)   |                        |                      |
| Ever OD                 |                        |                        |                        |                      |
| Yes                     | 77 (38.5)              | 57 (74.0)              | 20 (26.0)              | 1.53 (0.82–2.88)     |
| No                      | 123 (61.5)             | 80 (65.0)              | 43 (35.0)              | -                    |
| Drug treatment history  |                        |                        |                        |                      |
| Yes                     | 143 (71.5)             | 99 (69.2)              | 44 (30.8)              | 1.13 (0.58–2.17)     |
| No                      | 57 (28.5)              | 38 (66.7)              | 19 (33.3)              | -                    |

*p < 0.05

†In the last 6 months

*Opioids include Heroin, Hydros (Dilaudid and Hydromorph Contin), Generic Oxycodone, Oxy Neo, Percocet and Fentanyl
Table 2 Socio-demographic, drug use characteristics and treatment history characteristics associated with expected frequency of use among PWID willing to use SIS (n = 135)

| Characteristic | Willing to Use (n = 135) | Expected frequency of use | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|---------------|--------------------------|---------------------------|------------------------|----------------------|
|               |                          | Always/ Usually (n = 87)  | Sometimes/ Occasionally (n = 48) |                        |
| Age, yr       |                          | n (%                      | n (%)                  |                      |
| Median (IQR)  | 34 (27–43)               | 32 (25–41)                | 35 (20–48)             | 0.97 (0.94–1.01)      | 0.99 (0.94–1.02)      |
| Gender        |                          |                          |                        |                      |
| Female        | 57 (42.2)                | 43 (75.4)                 | 14 (24.6)              | 2.37* (1.12–5.03)     | 2.44* (1.06–5.65)     |
| Male          | 78 (57.8)                | 44 (56.4)                 | 34 (43.6)              |                       |                      |
| Ethnicity     |                          |                          |                        |                      |
| White         | 31 (23.0)                | 18 (58.1)                 | 13 (41.9)              | 1.42 (0.63–3.24)      | 1.08 (0.40–2.95)      |
| Other         | 104 (77.0)               | 69 (66.3)                 | 35 (33.7)              |                       |                      |
| Housing       |                          |                          |                        |                      |
| Unstable/Homeless | 98 (72.6)         | 64 (65.3)                 | 34 (34.7)              | 1.15 (0.52–2.51)      | 0.79 (0.31–1.97)      |
| Stable        | 37 (27.4)                | 23 (62.2)                 | 14 (37.8)              |                       |                      |
| Sex work      |                          |                          |                        |                      |
| Yes           | 30 (22.2)                | 21 (70.0)                 | 9 (30.0)               | 1.38 (0.57–3.31)      | -                    |
| No            | 105 (77.8)               | 66 (62.9)                 | 39 (37.1)              |                       |                      |
| Any public injecting<sup>a</sup> |                    |                          |                        |                      |
| Yes           | 103 (76.3)               | 71 (68.9)                 | 32 (31.1)              | 2.22 (0.99–4.98)      | 1.95 (0.78–4.88)      |
| No            | 32 (23.7)                | 16 (50.0)                 | 16 (50.0)              |                       |                      |
| Any injecting alone<sup>a</sup> |                  |                          |                        |                      |
| Yes           | 38 (28.1)                | 30 (78.9)                 | 8 (21.1)               | 2.63* (1.09–6.34)     | 2.59* (1.02–6.58)     |
| No            | 97 (71.9)                | 57 (58.8)                 | 40 (41.2)              |                       |                      |
| Any help injecting<sup>a</sup> |                   |                          |                        |                      |
| Yes           | 53 (39.3)                | 29 (54.7)                 | 24 (45.3)              | 0.50 (0.24–1.03)      | -                    |
| No            | 82 (60.7)                | 58 (70.7)                 | 24 (29.3)              |                       |                      |
| Syringe sharing<sup>a</sup> |                   |                          |                        |                      |
| Yes           | 13 (9.8)                 | 11 (84.6)                 | 2 (15.4)               | 3.33 (0.70–15.57)     | -                    |
| No            | 120 (90.2)               | 75 (62.5)                 | 45 (37.5)              |                       |                      |
| Daily opioid<sup>a</sup> injecting |                |                          |                        |                      |
| Yes           | 33 (24.4)                | 27 (81.8)                 | 6 (18.2)               | 3.15* (1.20–8.30)     | 2.64 (0.94–7.36)      |
| No            | 102 (75.6)               | 60 (58.8)                 | 42 (41.2)              |                       |                      |
| Daily cocaine injecting<sup>a</sup> |                |                          |                        |                      |
| Yes           | 30 (22.2)                | 24 (80.0)                 | 6 (20.0)               | 2.67 (1.00–7.08)      | -                    |
| No            | 105 (77.8)               | 63 (60.0)                 | 42 (40.0)              |                       |                      |
| Daily crack/rock cocaine injecting<sup>a</sup> |                |                          |                        |                      |
| Yes           | 16 (11.9)                | 13 (81.3)                 | 3 (18.7)               | 2.64 (0.71–9.76)      | -                    |
| No            | 119 (88.1)               | 74 (62.2)                 | 45 (37.8)              |                       |                      |
| Any Wellbutrin injecting<sup>a</sup> |                   |                          |                        |                      |
| Yes           | 50 (37.0)                | 32 (64.0)                 | 18 (36.0)              | -                    |                      |
| No            | 85 (63.0)                | 55 (64.7)                 | 30 (35.3)              | 0.97 (0.47–2.01)      | -                    |
| Any Ritalin or Biphentin injecting<sup>a</sup> |                   |                          |                        |                      |
| Yes           | 56 (41.5)                | 39 (69.6)                 | 17 (30.4)              | 1.48 (0.72–3.07)      | -                    |
| No            | 79 (58.5)                | 48 (60.8)                 | 31 (39.2)              |                       |                      |
women who use substances in this setting [65]. Given that we found women were more likely to use SIS at a higher expected frequency than men, SIS may provide a unique opportunity to engage with women. Tailored strategies for women who use drugs that may be considered in this setting include a women’s only SIS, women’s specific drop-in hours, women-centered health and social services, and case management [59, 66, 67].

Among PWID willing to use SIS, a high proportion was willing to walk (88%) or take a bus (78%) to access SIS. Participants were more willing to walk longer distances (more than 20 min) in summer months compared to winter months (63% vs. 31%). There was, however, less difference between summer and winter months in terms of time participants were willing to take the bus (64% vs. 63%). These findings are somewhat in contrast to past SIS feasibility work in a large urban Canadian centre, where 36% of PWID were willing to travel more than 20 min to use SIS [22], and more consistent with feasibility findings in other mid-size settings where 60 and 40% of PWID were respectively willing to walk to the service in summer and winter months [24]. These findings suggest that in contrast to SIS in large urban centres, PWID in small to mid-sized cities may be willing to travel greater distances to access harm reduction services. Of note, we also found that women were overall less willing to walk or bus to services, and less willing to travel longer distances compared to men. Given that women expressed greater expected frequency of SIS use, gender differences in willingness to travel, and barriers to transportation should be taken into consideration to maximize uptake of the service. While this study did not look at the acceptability of mobile services, complementing a fixed-site SIS with mobile services may be considered as a suitable alternative to ensure coverage of geographically dispersed PWID in the Thunder Bay region [68]. However, a previous analysis found mobile SIS to be less cost-effective than fixed SIS sites [69].

Regarding design and operational preferences, a majority of participants preferred daytime hours of operation and private cubicles for injecting space set-up, while over half believed PWID should be involved in the day-to-day operations of service delivery. Involvement of peers in the delivery of harm reduction services may offer a unique opportunity to engage this typically hard-to-reach population, while also conferring benefits for the peers themselves [70]. Finally, in addition to naming a number of other harm reduction services to provide alongside SIS (i.e. distribution of sterile needles and injecting equipment and harm reduction education), other amenities deemed important include access to basic medical care, withdrawal management and the availability of washrooms. A similar combination of amenities, in addition to access to nursing staff, peer support, HIV/HCV testing, and referrals to drug treatment and services, were also identified in past feasibility studies conducted in the Canadian context [22, 24], highlighting PWIDs’ perspective of SIS as an integrated hub for health and wellbeing, beyond just a place to inject drugs.

This study has limitations. First, it relied on data from a non-randomized sample PWID and therefore may not be representative of all PWID in Thunder Bay. Similar to other studies with PWID, participants were recruited through diverse methods, including peer outreach efforts, word-of-mouth, and recruitment materials through local health and service organizations and therefore, our sample may be more likely to represent PWID willing to engage with health and harm reduction services, such as SIS. With the assistance of PRAs, efforts were made to recruit participants from a range of settings. However, this may have led to some groups or networks of individuals being over-represented in our sample. Second, having relied on self-reported responses obtained by PRAs, the data may have been subject to reporting biases including social desirability and

| Characteristic | Willing to Use (n = 135) | Expected frequency of use | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|---------------|-------------------------|---------------------------|-----------------------|---------------------|
| Ever OD       |                         |                           |                       |                     |
| Yes           | 57 (42.2)               | 41 (71.9)                 | 16 (28.1)             | 1.78 (0.86–3.71)    |
| No            | 78 (57.8)               | 46 (59.0)                 | 32 (41.0)             |                     |
| Drug treatment history |               |                           |                       |                     |
| Yes           | 97 (71.9)               | 64 (66.0)                 | 33 (34.0)             | 1.27 (0.58–2.74)    |
| No            | 38 (28.1)               | 23 (60.5)                 | 15 (39.5)             |                     |

*p < 0.05

*In the last 6 months

Opioids include Heroin, Hydros (Dilaudid and Hydromorph Contin), Generic Oxycodone, Oxy Neo, Percocet and Fentanyl

**Table 2** Socio-demographic, drug use characteristics and treatment history characteristics associated with expected frequency of use among PWID willing to use SIS (n = 135) (Continued)**
recall bias. Nonetheless, past research suggests that self-reported responses from PWID are valid and reliable [71].

**Conclusions**

In summary, we found moderately high levels of willingness to use SIS among PWID in Thunder Bay, Canada. Willingness to use SIS was positively associated with public injecting and higher expected frequency of use was associated with being female and injecting alone. Findings of the present study highlight the potential of SIS in addressing the harms associated with injection drug use in this remote and mid-sized setting, particularly among those who are most vulnerable. If implemented in Thunder Bay, to optimize the uptake of services, program planners and policy-makers should take into consideration the preferences and characteristics of local PWID, while also recognizing the unique challenges faced by PWID and harm reduction services in locations that serve the diverse needs of suburban, rural, and remote communities.

**Abbreviations**

AOR: Adjusted odds ratio; CI: Confidence interval; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; OIS: Ontario Integrated Supervised Injection Services; OR: Odds ratio; PRA: Peer research associate; PWID: People who inject drugs; SIS: Supervised injection services; TBDHU: Thunder Bay District Health Unit

**Acknowledgements**

We would like to thank all study participants. We would also like to thank the following individuals and organizations for their contributions to the study: Jasmine Cotnam, Marsha Ledger, Rebecca Gower, members of the

| Table 3 Design preferences and important amenities identified for SIS among PWID willing to use SIS (n = 137) |
|---------------------------------------------------------------|
| **Design feature**                                            | **Total** | **Males** | **Females** |
|                                                               | (n = 137) | (n = 78)  | (n = 59)    |
| Willing to walk to SIS                                        |           |           |            |
| Willing to walk 20 min or more during Summer months           |            |           |            |
| Willing to walk 20 min or more during Winter months           |            |           |            |
| Willing to take a bus to SIS                                  |            |           |            |
| Willing to take a bus for 20 min or more during Summer months |            |           |            |
| Willing to take a bus for 20 min or more during Winter months |            |           |            |
| Preferred set-up for injecting space                          |            |           |            |
| Private cubicle                                               |            |           |            |
| An open plan with benches at one large table or counter       |            |           |            |
| An open plan with tables and chairs                          |            |           |            |
| A combination of above                                         |            |           |            |
| Preferred operating hours                                     |            |           |            |
| Daytime                                                       |            |           |            |
| Evening                                                       |            |           |            |
| Overnight                                                     |            |           |            |
| Involvement of PWID in SIS operation                          |            |           |            |
| Important amenities identified for SIS                        |            |           |            |
| Needle distribution                                           |            |           |            |
| Distribution of sterile injection equipment                   |            |           |            |
| Preventing or responding to overdose                          |            |           |            |
| Access to health services                                     |            |           |            |
| HIV/HCV testing                                               |            |           |            |
| Withdrawal Management                                         |            |           |            |
| Washrooms                                                     |            |           |            |
| Nursing staff for medical care and supervised injection teaching|            |           |            |
| Harm reduction education                                      |            |           |            |
| Referrals to drug treatment, rehab, and other services when ready to use| | | |

NS not significant at \( p < 0.05 \) level

\* \( p < 0.05 \)

\** \( p < 0.01 \)

\*** \( p < 0.001 \)
Advisory Committee, ElevateNWO, Shelter House, and People Advocating for Change Through Empowerment (PACE). This study was conducted by the Ontario HIV Treatment Network, in collaboration with the Thunder Bay Drug Strategy.

Funding
This study was funded by the Canadian Institutes of Health Research (CIHR) Centre for Reach in HIV/AIDS and Thomas Kerr’s CIHR Foundation Grant (FDN-148476). The funding agencies had no role in the study design, data collection, analyses and interpretation of the data, or preparation of the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
TK designed the Ontario Integrated Supervised Injection Services Feasibility Study. BK, SM, CO and were responsible for the day-to-day running of the research study and acquired the data. BR conducted the analysis. SM drafted the manuscript and incorporated suggestions from all co-authors. TK, BK, SM, CO, BR, ZM, SR contributed to the interpretation of findings and revision of the manuscript for intellectual content. All authors reviewed and approved the final version of the published manuscript.

Ethics approval and consent to participate
Ethical approval was obtained from the University of Toronto and University of British Columbia’s research ethics boards. All participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. DeWitt DE, Pauw DS. Endocarditis in injection drug users. Am Fam Physician. 1996;53(6):2045–9.
2. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment: for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268–84.
3. Lorch J, Kral AH, Seal K, Gere L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health. 2001;91(1):46–7.
4. Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health. 2008;8:405.
5. Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JS, et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Can Med Assoc J. 2004;171(7):731–4.
6. Palepu A, Tyndall MW, Leon H, Muller J, O’Shaughnessy MV, Schechter MT, et al. Hospital utilization and costs in a cohort of injection drug users. Can Med Assoc J. 2001;165(4):415–20.
7. Wood E, Kerr T, Spittal PM, Tyndall MW, O’Shaughnessy MV, Schechter MT. The healthcare and fiscal costs of the illicit drug use epidemic: the impact of conventional drug control strategies and the impact of a comprehensive approach. BC Medical J. 2003;45(3):130–6.
8. Kimber J, Dolan K, Wodak A. Survey of drug consumption rooms: service delivery and perceived public health and amenity impact. Drug Alcohol Rev. 2005;24(1):21–4.
9. Broadhead RS, Kerr TH, Grund JPC, Altice FL. Safer injection facilities in North America: their place in public policy and health initiatives. J Drug Issues. 2002;32(1):329–45.
10. Heddych D, Kerr T, Dubois-Arber F. Drug consumption facilities in Europe and beyond. In: Rhodes T, Heddych D, editors. Harm reduction: evidence, impacts, and challenges. Luxembourg: European Monitoring Centre for Drug and Drug Addiction, 2010.
11. Krusi A, Small W, Wood E, Kerr T. An integrated supervised injecting program within a care facility for HIV-positive individuals: a qualitative evaluation. AIDS Care. 2009;21(S6):338–44.
12. Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh DC, Montaner JSG, Tyndall MW. Methodology for evaluating Insite: Canada’s first medically supervised safer injection facility for injection drug users. Harm Reduct J. 2004;1:9.
13. Lafraamboise K. Montreal’s supervised injection sites open, a first in eastern Canada. CBC News. 2017. https://www.cbc.ca/news/canada/montreal/montreal-supervised-injection-sites-open-2017-1-4166638. (Accessed 16 Nov 2016).
14. Jones A, Ontario agrees to fund Toronto and Ottawa safe injection sites amid opioid crisis. CTV News. 2017. https://www.ctvnews.ca/health/ontario-agrees-to-fund-toronto-and-ottawa-safe-injection-sites-amid-opioid-crisis-1.3235336. (Accessed 16 Nov 2016).
15. Salmon A, van Beek I, Amin J, Kaldor J, Maher L. The impact of a supervised injecting facility on ambulance call-outs in Sydney. Australia Addiction. 2010;10(6):676–83.
16. Stoltz JA, Wood E, Small W, Li K, Tyndall M, Montaner J, et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health. 2007;29(1):35–9.
17. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011; 377(9776):1429–37.
18. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005;366(9482):316–8.
19. Wood E, Tyndall MW, Zhang R, Montaner J, Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction. 2007;102(6):916–9.
20. Wood E, Tyndall MW, Zhang R, Stoltz JA, Lai C, Montaner JS, et al. Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med. 2006;354(23):2512–4.
21. Salmon AM, Thein R, Kimber J, Kaldor J, Maher L. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney medically supervised injecting centre? Int J Drug Policy. 2007;18(1):46–53.
22. Bayoumi, Strickland SA, Brandeau M, Degani N, Fischer B, Glazier R, et al. Report on the Toronto and Ottawa Supervised Consumption Assessment Study. 2012. https://www.catr.ca/sites/default/files/TOCSAI%20Report%202012.pdf. (Accessed 16 Nov 2016).
23. Kral AH, Wengler L, Carpenter L, Wood E, Kerr T, Bourgois P. Acceptability of a safer injection facility among injection drug users in San Francisco. Drug Alcohol Depend. 2010;110(1–2):160–5.
24. Mitra S, Ratchis B, Schein A, Bawerly G, Rouke SB, Kerr T. Acceptability and design preferences of supervised injection services among people who inject drugs in a mid-sized Canadian City. Harm Reduct J. 2017;14(1):46.
25. Wood E, Kerr T, Spittal PM, Li K, Small W, Tyndall MW, et al. The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users. J Acquir Immune Defic Syndr. 2003;32(1):2–8.
26. Kerr T, Wood E, Small D, Palepu A, Tyndall MW. Potential use of safer injecting facilities among injection drug users in Vancouver’s downtown eastside. Can Med Assoc J. 2003;169(8):759–63.

27. DeBeck K, Kerr T, Lai C, Buxton J, Montaner J, Wood E. The validity of reporting willingness to use a supervised injecting facility on subsequent program use among people who use injection drugs. Am J Drug Alcohol Abuse. 2012;38(5):55–62.

28. Elib JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after Federal Oversight. Can J Psychiatry. 2017;62(7):444–50.

29. Hardil K. Below the radar: an exploration of substance use in rural Ontario; 2011.

30. Simard M, Simard C. Toward a culturalist city: a planning agenda for peripheral mid-size cities. Can J Urban Res. 2005;14(1):39–66.

31. Randall T, Kavalchuk T, Nelson R. Metrics of urban sustainability: a case study of changing downtowns in Thunder Bay. Canada Sustainabililty. 2017;9:1272.

32. Statistics Canada. Thunder Bay, Ontario. Ottawa: Census Profile; 2017.

33. Thunder Bay District Health Unit. Our Locations. 2018. https://www.tbdu.ca/about-us/our-locations. (Accessed 7 Jan 2019).

34. Bosman J. Inside a killer drug epidemic: a look at America’s opioid crisis. New York Times. 2017. (Accessed 20 Nov 2019).

35. Gustafson DL, Goodyear L, Keough F. When the dragon awakes: a needs assessment of people injecting drugs in a small urban Centre. Int J Drug Policy. 2008;19(3):189–94.

36. Draus P, Carlson RG. Down on main street: drugs and the small-town vortex. Health Place. 2009;15(1):247–54.

37. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Recommendations for the public health response to Hepatitis C in Ontario. Provincial Infectious Diseases Advisory Committee. Toronto: Queen’s Printer for Ontario; 2014.

38. City of Thunder Bay. Drug strategy accommodation needs assessment: a community plan for Thunder Bay. 2013. https://www.thunderbay.ca/en/city-hall/resources/Documents/ThunderBayDrugStrategy/DrugStrategy-Accommodation-Needs-Assessment---Community-Plan---May-2013.pdf. (Accessed 30 Oct 2017).

39. Sawula E, Greenaway J, Olsen C, Jaun A, Flanagan Q, Leiterman A, Groot E. Opioid Use and Impacts in Thunder Bay District. Thunder Bay: Thunder Bay District Health Unit; 2018.

40. Public Health Agency of Canada. I-Track: Enhanced surveillance of HIV, Hepatitis C and associated risk behaviours among people who inject drugs in Canada. Phase 2 Report. Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada; 2013.

41. Millson P, White S. Ontario I-Track Report. Toronto: Enhanced Surveillance of HIV, Hepatitis C and associated risk behaviours among people who inject drugs. Ontario District Health Unit; 2018.

42. Millson P, Leonard L, Remis RS, Strike C, Challacombe L. Injection drug use, HIV and HCV infection in Ontario. The evidence 1992 to 2004. Toronto: 2005.

43. Ontario Harm Reduction Distribution Program. Needle Syringe Programs. 2018. http://www.ohdp.ca/about-us/needle-exchange/. (Accessed 20 Dec 2018).

44. Murray J. A Dose of Thunder Bay Reality. NNL Newsledger. 2013. http://www.nnledger.com/2013/10/27/dose-thunder-bay-reality/. (Accessed 20 Nov 2017).

45. Thunder Bay Drug Strategy. Roadmap for Change: Towards a Safe and Healthy Community. 2011. https://www.thunderbay.ca/en/city-hall/resources/Documents/ThunderBayDrugStrategy/2011-Roadmap-for-Change.pdf. (Accessed 30 Nov 2017).

46. Kerr T, Mitra S, Krysovaty B, Marshall Z, Olsen C, Rachlis B, et al. The Ontario Integrated Supervised Feasibility Study Report. Thunder Bay. 2017. http://www.ohtn.on.ca/wp-content/uploads/2017/02/OISS- ThunderBay-Report-Online.pdf. (Accessed 16 Feb 2017).

47. Kerr T, Schein A, Bardwell G, Mitra S, Rachlis B, Bacon J, et al. London: The Ontario Integrated Supervised Feasibility Study Report. 2017. http://www.ohtn.on.ca/wp-content/uploads/2017/02/OISS-London-Report-Onlin.pdf. (Accessed 16 Feb 2017).

48. Biedts KS, Chan C, Mohannaith F, Dietze P, Whitaker E, Burns L, et al. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies. Addiction. 2016;111(7):1214–23.

49. SAS. SAS Institute Inc. SAS Version 9.4. Cary, 2013.

50. Thomas K, Scruton S. Rural and Remote Needs Assessment. Ottawa; 2014.

51. The Canadian Harm Reduction Network & Canadian AIDS Society. Learning from each other: enhancing community-based harm reduction programs and practice in Canada. 2008.

52. Small W, Rhodes T, Wood E, Kerr T. Public injection settings in Vancouver: physical environment, social context and risk. Int J Drug Policy. 2007;18(1):27–36.

53. Rhodes T, Kimber J, Small W, Fitzgerald J, Kerr T, Hickman M, et al. Public injecting and the need for ‘safer environment interventions’ in the reduction of drug-related harm. Addiction. 2006;101(10):1384–93.

54. DeBeck K, Small W, Wood E, Li K, Montaner J, Kerr T. Public injecting among a cohort of injecting drug users in Vancouver. Canada J Epidemiol Community Health. 2009;63(1):81–6.

55. Dovey K, Fitzgerald J, Choi S. Safety becomes dangerous: dilemmas of drug-use in public space. Health Place. 2001;7(4):319–31.

56. Davidson PJ, McLean RL, Kral AHG, Gleghorn AA, Edlin BR, Moss A. Fatal heroin-related overdose in San Francisco, 1997–2000: a case for targeted intervention. J Urban Health. 2003;80(2):261–73.

57. Wood E, Tyndall MW, Spittal PM, Li K, Kerr T, Hogg RS, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ. 2001;165(4):405–10.

58. Hagan H, Campbell JV, Thiede H, Strathdee SA, Ouellet L, Latka M, et al. Injecting alone among young adult IDUs in five US cities: evidence of low rates of injection risk behavior. Drug Alcohol Depend. 2007;91(Suppl 1):S48–55.

59. Greenfield S, Grella C. Alcohol & Drug Abuse: what is “women-focused” Treatment for substance use disorders? Psychiatr Serv. 2009;60(7):880–2.

60. National Institute on Drug Abuse. Sex and Gender Differences in Substance Use. 2017. https://www.drugabuse.gov/publications/research-reports/substance-use-in-women/sex-gender-differences-in-substance-use. (Accessed 14 Aug 2017).

61. Azim T, Bontell I, Strathdee SA, Women, drugs and HIV. Int J Drug Policy. 2015;26(Suppl 1):S16–21.

62. Centre for Substance Abuse Treatment. Substance abuse treatment: addressing the specific needs of women. In: Treatment improvement protocol (TIP) series 51. HHS publication no. (SMA) 09-4426. Rockville: Substance Abuse and Mental Health Services Administration; 2009.

63. Greenfield S, Back S, Lawson K, Brady K. Substance abuse in women. Psychiatr Clin North Am. 2010;33(2):339–55.

64. Fairbairn N, Small W, Shannon K, Wood E, Kerr T. Seeking refuge from violence in street-based drug scenes: women’s experiences in North America’s first supervised injection facility. Soc Sci Med. 2008;67(5):817–23.

65. Kashak D. An overview of issues, impacts and services for women who are using substances and are pregnant or parenting within the City of Thunder Bay, Thunder Bay: The Thunder Bay Drug Strategy; 2015.

66. Poole N, Urquhart C, Talbot C. Women-Centred harm reduction. Vancouver: British Columbia Centre of Excellence for Women’s Health; 2010.

67. Vancouver Coastal Health. New substance treatment services for women on the Downtown Eastside. 2017. http://www.vch.ca/about-us/news/news-releases/new-substance-treatment-services-for-women-on-the-Downtown-Eastside. (Accessed 16 Nov 2017).

68. Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017;14(1):28.

69. Dietze P, Winter R, Pedrana A, Leicht A, Majo IRX, Brugal MT. Mobile safe injecting facilities in Barcelona and Berlin. Int J Drug Policy. 2012;23(4):257–60.

70. Marshall Z, Dechman MK, Minichiello A, Alcock L, Harris GE. Peering into the women’s experiences in North side of the Downtown Eastside. 2017. http://www.vch.ca/about-us/news/news-releases/new-substance-treatment-services-for-women-on-the-Downtown-Eastside. (Accessed 16 Nov 2017).

71. Drake S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:253–63.

72. Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions